Hospitals and universities repurposing drugs at lower cost
How patients find repurposing studies
- Similar channels as other clinical trials: big health systems’ or universities’ mailing lists, public trial registries (e.g., clinicaltrials.gov), and disease‑specific patient communities.
- Specialists often know emerging evidence first and may suggest off‑label options.
- Some participants report positive experiences in clinical trials.
Regulation, patents, and off‑label use
- Off‑label prescribing is described as extremely common, especially for complex or rare conditions.
- Disagreement over whether new uses of old drugs can be patented; some say yes (with legal citations), others say it’s hard or not possible in practice.
- In the US, anyone can in principle file a new drug application for an existing compound, but practical control over manufacturing usually requires involvement of or becoming a manufacturer.
- In the UK, doctors can prescribe unlicensed uses, but official care “pathways” and liability issues matter.
- FDA’s process is seen as optimized for initial indication approval, not for systematically updating labels for new uses.
Insurance coverage and incentives
- Conflicting claims on whether insurers “typically” refuse to cover off‑label use; multiple commenters say coverage is routine, sometimes with prior authorization, especially for cheaper drugs.
- Others note insurers are not required to cover off‑label use, and coverage can be difficult for expensive treatments.
- Some argue US insurers have perverse incentives: medical loss ratio rules mean higher care costs can translate into higher absolute profits.
- Self‑insured employers and public programs (Medicare, Medicaid, VA, etc.) may have different incentives, but their reach is debated.
Examples of repurposed or off‑label drugs
- Low‑dose naltrexone (LDN) used off‑label (e.g., for ME/CFS, Long COVID); several users report substantial benefit.
- Gabapentin, approved for seizures, widely used off‑label for neuropathic pain.
- Esketamine (Spravato) vs generic ketamine for depression: same basic molecule family, but esketamine is patented, FDA‑approved, and vastly more expensive; some claim ketamine is more effective yet harder to get covered.
- Bevacizumab (Avastin) vs Lucentis for macular degeneration: similar targeting; Avastin is much cheaper but must be repackaged by compounding pharmacies, raising contamination risk. Past compounding disasters are cited.
- Cancer drugs and other existing agents are being trialed for blindness, Huntington’s disease, and other conditions via nonprofits and academic centers.
Drug pricing, markets, and capitalism
- US brand‑name drug prices are seen as driven by patent‑backed monopolies; generics are noted as relatively cheap.
- Debate over whether the US is “maximally capitalist” or better described as a regulated, monopoly‑friendly system.
- Some argue monopolies and patent law are anti‑competitive; others note patents are a deliberate tradeoff to force disclosure instead of trade secrets.
- There is discussion of prize models, “open‑sourcing” taxpayer‑funded drug discoveries, and government‑run, transparent clinical trials to break monopoly control.
Role of government vs private sector
- One side: government must fund baseline research and trials; unregulated markets (e.g., supplements) show how bad quality can be.
- Other side: skepticism that government programs stay efficient; risk of bureaucracy and political incentives distorting priorities.
- General agreement that current incentives (FDA risk‑aversion, pharma profit motives, insurance structures) make repurposing underused relative to its potential.
Benefits and limits of repurposing
- Repurposing is seen as powerful for rare diseases and for cheaper symptom control.
- Commenters stress it cannot replace new drug development, especially for conditions like some forms of Long COVID and ME/CFS, where no effective repurposed options have emerged.
- Several note that repurposing is most pursued once patents expire, often by universities and hospitals with limited commercial incentive.